15 / 39
OS by Duration of First-Line Therapy in Patients With mRCC
No. of patients at risk
Nivolumab
110
90
68
47
12
1
Everolimus
130
87
67
47
11
2
Overall Survival (Probability)
0
3
6
12
9
15
Months
18
21
24
27
30
33
Nivolumab
Everolimus
0.0
0.1
0.8
0.9
0.2
0.3
0.4
0.5
0.6
0.7
1.0
0
3
6
12
9
15
Months
18
21
24
27
30
33
Nivolumab
Everolimus
300
269
237
166
61
2
281
237
198
140
50
0
0.0
0.1
0.8
0.9
0.2
0.3
0.4
0.5
0.6
0.7
1.0
HR (95% CI
), 0.76 (0.55–1.06)
Median OS, months
(95% CI)
Nivolumab
18.2 (13.9–25.0)
Everolimus
14.0 (9.7–18.1)
<6 months
HR (95% CI
), 0.78 (0.61–0.99)
Median OS, months
(95% CI)
Nivolumab
27.4 (23.2–NE)
Everolimus
22.8 (19.7–NE)
>6 months
Based on data cut-off of June 2015. Motzer RJ et al. Oral presentation at ASCO GU 2016.498.